Prevalence, Incidence and Treatment Patterns of Prurigo Nodularis in England: A Retrospective Database Analysis

Prurigo nodularis (PN) is a pruritic skin disease characterised by multiple, intensely itchy skin nodules in symmetrically distributed areas of the extremities. There are very limited studies on the epidemiology and treatment pathways for PN, especially moderate-to-severe PN, from England. To assess...

Full description

Saved in:
Bibliographic Details
Published in:British journal of dermatology (1951) Vol. 191; no. 4; p. 548
Main Authors: Bahloul, Donia, Hudson, Richard, Balogh, Orsolya, Mathias, Elgan, Heywood, Ben, Hubbuck, Ellen, Diribe, Onyinye, McDonald, Robert, Bewley, Anthony
Format: Journal Article
Language:English
Published: England 04-06-2024
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract Prurigo nodularis (PN) is a pruritic skin disease characterised by multiple, intensely itchy skin nodules in symmetrically distributed areas of the extremities. There are very limited studies on the epidemiology and treatment pathways for PN, especially moderate-to-severe PN, from England. To assess the epidemiology and treatment pathways of mild and moderate-to-severe PN in England. This retrospective cohort study used data from the Clinical Practice Research Datalink (CPRD) and Hospital Episode Statistics (HES) in England. Adult patients (≥18 years) with a PN specific diagnosis code any time between 1 April 2007 and 1 March 2019 (patient identification period) were selected. Patients were included if their first PN diagnostic code (index diagnosis date, IDD) was recorded during the identification period, with data available 6 months pre- and ≥12 months post-IDD. Patients were classified into moderate-to-severe PN (MSPN) or mild PN (MiPN) based on the presence or absence of a prescription record, post IDD, for either a systemic immunosuppressant or a gabapentinoid. Patients with MSPN and MiPN were matched 1:1 for age, gender and IDD. Prevalence and incidence were calculated for each year from 2007 to 2019. Drugs prescribed post IDD were analysed. A total of 8,933 patients (MSPN: 2,498 patients; MiPN: 6,539 patients) were included for the study; 2,462 patients each with MiPN and MSPN were included for the comparative analysis. Atopic dermatitis, asthma and eosinophilic oesophagitis were significantly higher (all p<0.001) in patients with MSPN (vs MiPN). The prevalence of overall PN cases increased during the study period. The incidence rate also showed a similar trend. The rates of prescription of potent and super potent topical corticosteroids (TCS), topical calcineurin inhibitors, first- and second- generation antihistamines, oral and injectable systemic corticosteroid, methotrexate, antidepressants and tacrolimus were significantly higher (all p <0.001) in patients with MSPN (vs MiPN). The epidemiology of PN was consistent with other European studies. Patients with MSPN received a significantly higher number of prescriptions for potent TCS and systemic drugs, as compared with milder patients.
AbstractList Prurigo nodularis (PN) is a pruritic skin disease characterised by multiple, intensely itchy skin nodules in symmetrically distributed areas of the extremities. There are very limited studies on the epidemiology and treatment pathways for PN, especially moderate-to-severe PN, from England. To assess the epidemiology and treatment pathways of mild and moderate-to-severe PN in England. This retrospective cohort study used data from the Clinical Practice Research Datalink (CPRD) and Hospital Episode Statistics (HES) in England. Adult patients (≥18 years) with a PN specific diagnosis code any time between 1 April 2007 and 1 March 2019 (patient identification period) were selected. Patients were included if their first PN diagnostic code (index diagnosis date, IDD) was recorded during the identification period, with data available 6 months pre- and ≥12 months post-IDD. Patients were classified into moderate-to-severe PN (MSPN) or mild PN (MiPN) based on the presence or absence of a prescription record, post IDD, for either a systemic immunosuppressant or a gabapentinoid. Patients with MSPN and MiPN were matched 1:1 for age, gender and IDD. Prevalence and incidence were calculated for each year from 2007 to 2019. Drugs prescribed post IDD were analysed. A total of 8,933 patients (MSPN: 2,498 patients; MiPN: 6,539 patients) were included for the study; 2,462 patients each with MiPN and MSPN were included for the comparative analysis. Atopic dermatitis, asthma and eosinophilic oesophagitis were significantly higher (all p<0.001) in patients with MSPN (vs MiPN). The prevalence of overall PN cases increased during the study period. The incidence rate also showed a similar trend. The rates of prescription of potent and super potent topical corticosteroids (TCS), topical calcineurin inhibitors, first- and second- generation antihistamines, oral and injectable systemic corticosteroid, methotrexate, antidepressants and tacrolimus were significantly higher (all p <0.001) in patients with MSPN (vs MiPN). The epidemiology of PN was consistent with other European studies. Patients with MSPN received a significantly higher number of prescriptions for potent TCS and systemic drugs, as compared with milder patients.
Prurigo nodularis (PN) is a pruritic skin disease characterized by multiple intensely itchy skin nodules in symmetrically distributed areas of the extremities. There are limited studies on the epidemiology and treatment pathways of PN, especially moderate-to-severe PN, from England.BACKGROUNDPrurigo nodularis (PN) is a pruritic skin disease characterized by multiple intensely itchy skin nodules in symmetrically distributed areas of the extremities. There are limited studies on the epidemiology and treatment pathways of PN, especially moderate-to-severe PN, from England.To assess the epidemiology and treatment pathways of mild and moderate-to-severe PN in England.OBJECTIVESTo assess the epidemiology and treatment pathways of mild and moderate-to-severe PN in England.This retrospective cohort study used data from the Clinical Practice Research Datalink and Hospital Episode Statistics in England. Adult patients (aged ≥ 18 years) with a PN-specific diagnosis code allocated any time between 1 April 2007 and 1 March 2019 (patient identification period) were selected. Patients were included if their first PN diagnostic code (index diagnosis date; IDD) was recorded during the identification period, with data available 6 months before and ≥ 12 months after the IDD. Patients were classified as having moderate-to-severe PN (MSPN) or mild PN (MiPN), based on the presence or absence of a prescription record, post-IDD, for either a systemic immunosuppressant or a gabapentinoid. Patients with MSPN and MiPN were matched 1 : 1 according to age, sex and IDD. Prevalence and incidence were calculated for each year from 2007 to 2019. Drugs prescribed post-IDD were analysed.METHODSThis retrospective cohort study used data from the Clinical Practice Research Datalink and Hospital Episode Statistics in England. Adult patients (aged ≥ 18 years) with a PN-specific diagnosis code allocated any time between 1 April 2007 and 1 March 2019 (patient identification period) were selected. Patients were included if their first PN diagnostic code (index diagnosis date; IDD) was recorded during the identification period, with data available 6 months before and ≥ 12 months after the IDD. Patients were classified as having moderate-to-severe PN (MSPN) or mild PN (MiPN), based on the presence or absence of a prescription record, post-IDD, for either a systemic immunosuppressant or a gabapentinoid. Patients with MSPN and MiPN were matched 1 : 1 according to age, sex and IDD. Prevalence and incidence were calculated for each year from 2007 to 2019. Drugs prescribed post-IDD were analysed.A total of 8933 patients (MSPN, n = 2498; MiPN, n = 6435) were included in the study; 2462 patients with MiPN and 2462 with MSPN were included for the comparative analysis. The presence of atopic dermatitis, asthma and eosinophilic oesophagitis were significantly higher (all P < 0.001) in patients with MSPN compared with those with MiPN. The overall prevalence of cases of PN increased during the study period. The incidence rate also showed a similar trend. The rates of prescription of potent and super-potent topical corticosteroids (TCS), topical calcineurin inhibitors, first- and second-generation antihistamines, oral and injectable systemic corticosteroids, methotrexate, antidepressants and tacrolimus were significantly higher (all P < 0.001) in patients with MSPN compared with those with MiPN.RESULTSA total of 8933 patients (MSPN, n = 2498; MiPN, n = 6435) were included in the study; 2462 patients with MiPN and 2462 with MSPN were included for the comparative analysis. The presence of atopic dermatitis, asthma and eosinophilic oesophagitis were significantly higher (all P < 0.001) in patients with MSPN compared with those with MiPN. The overall prevalence of cases of PN increased during the study period. The incidence rate also showed a similar trend. The rates of prescription of potent and super-potent topical corticosteroids (TCS), topical calcineurin inhibitors, first- and second-generation antihistamines, oral and injectable systemic corticosteroids, methotrexate, antidepressants and tacrolimus were significantly higher (all P < 0.001) in patients with MSPN compared with those with MiPN.The epidemiology of PN was consistent with that found in other European studies. Patients with MSPN received a significantly higher number of prescriptions for potent TCS and systemic drugs compared with patients with MiPN.CONCLUSIONSThe epidemiology of PN was consistent with that found in other European studies. Patients with MSPN received a significantly higher number of prescriptions for potent TCS and systemic drugs compared with patients with MiPN.
Author Bahloul, Donia
Heywood, Ben
Mathias, Elgan
Balogh, Orsolya
Hudson, Richard
Hubbuck, Ellen
Diribe, Onyinye
Bewley, Anthony
McDonald, Robert
Author_xml – sequence: 1
  givenname: Donia
  orcidid: 0009-0008-9887-8159
  surname: Bahloul
  fullname: Bahloul, Donia
  organization: Sanofi, Gentilly, France
– sequence: 2
  givenname: Richard
  surname: Hudson
  fullname: Hudson, Richard
  organization: Sanofi, Reading, UK
– sequence: 3
  givenname: Orsolya
  surname: Balogh
  fullname: Balogh, Orsolya
  organization: Sanofi, Reading, UK
– sequence: 4
  givenname: Elgan
  surname: Mathias
  fullname: Mathias, Elgan
  organization: Human Data Sciences, Cardiff, UK
– sequence: 5
  givenname: Ben
  surname: Heywood
  fullname: Heywood, Ben
  organization: Human Data Sciences, Cardiff, UK
– sequence: 6
  givenname: Ellen
  surname: Hubbuck
  fullname: Hubbuck, Ellen
  organization: Human Data Sciences, Cardiff, UK
– sequence: 7
  givenname: Onyinye
  surname: Diribe
  fullname: Diribe, Onyinye
  organization: Sanofi, Reading, UK
– sequence: 8
  givenname: Robert
  surname: McDonald
  fullname: McDonald, Robert
  organization: Sanofi, Reading, UK
– sequence: 9
  givenname: Anthony
  surname: Bewley
  fullname: Bewley, Anthony
  organization: Dermatology Department, Royal London Hospital, Barts Health NHS Trust, London, UK
BackLink https://www.ncbi.nlm.nih.gov/pubmed/38832950$$D View this record in MEDLINE/PubMed
BookMark eNo9kE1LAzEQhoMo2lZP3iVHQddOdvbTW6lfhaJFel-SzVS27GZrkhX6741YPc3A-8zL8IzZsekNMXYp4E5AiVO11dN2KymG_IiNBGZpFAvEYzYCgDyCMsMzNnZuCyAQUjhlZ1gUGJcpjFi_svQlWzI13fKFqRv9s3JpNF9bkr4j4_lKek_WON5v-MoOtvno-Wuvh1baxvHG8Efz0YaTez7j7-Rt73ZU--aL-IP0UklHfGZku3eNO2cnG9k6ujjMCVs_Pa7nL9Hy7Xkxny2jOhaJj5QGzFEnQmVIgAqIMlIJJUkBZaFUSMuYRJrFWVGERGmdQaJwIxRkSY4Tdv1bu7P950DOV13jamrDl9QPrsJApUWMZRnQm1-0Dn87S5tqZ5tO2n0loPoRXAXB1UFwoK8OxYPqSP-zf0bxG02HecU
Cites_doi 10.3414/ME11-02-0023
10.1016/j.det.2018.02.003
10.2340/00015555-3655
10.1002/ejp.767
10.3390/jcm11010095
10.1016/j.jdin.2020.10.009
10.1016/j.jaad.2020.07.025
10.2340/00015555-3518
10.1111/jdv.14570
10.1111/jdv.15107
10.1111/jdv.15040
10.1056/NEJMoa1908316
10.1016/j.jaad.2021.05.036
10.1093/ije/dyz034
10.1097/itx.0000000000000042
10.1111/bjd.21032
10.2147/CCID.S208964
10.1016/j.jaad.2018.04.047
10.3389/fmed.2022.1022889
10.1016/j.jid.2019.07.697
10.2147/CCID.S188070
10.3389/fmed.2022.1011142
10.3109/09546634.2013.814759
ContentType Journal Article
Copyright The Author(s) 2024. Published by Oxford University Press on behalf of British Association of Dermatologists.
Copyright_xml – notice: The Author(s) 2024. Published by Oxford University Press on behalf of British Association of Dermatologists.
DBID NPM
AAYXX
CITATION
7X8
DOI 10.1093/bjd/ljae207
DatabaseName PubMed
CrossRef
MEDLINE - Academic
DatabaseTitle PubMed
CrossRef
MEDLINE - Academic
DatabaseTitleList PubMed
MEDLINE - Academic
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1365-2133
ExternalDocumentID 10_1093_bjd_ljae207
38832950
Genre Journal Article
GroupedDBID ---
.3N
.GA
05W
0R~
10A
1OC
23N
33P
36B
3SF
4.4
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
5GY
5HH
5LA
5RE
5VS
5WD
66C
6P2
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A01
A03
AABZA
AACZT
AAESR
AAEVG
AAHHS
AAONW
AAPXW
AARHZ
AAUAY
AAVAP
AAXRX
AAZKR
ABCQN
ABCUV
ABEJV
ABNHQ
ABOCM
ABPTD
ABPVW
ABQNK
ABWST
ABXGK
ABXVV
ACAHQ
ACCFJ
ACCZN
ACFBH
ACGFS
ACMXC
ACPOU
ACPRK
ACUTJ
ACXBN
ADBBV
ADEOM
ADIPN
ADIZJ
ADKYN
ADMGS
ADOZA
ADQBN
ADVEK
ADXAS
ADZMN
ADZOD
AEEZP
AEIMD
AENEX
AEQDE
AEUQT
AFBPY
AFEBI
AFGKR
AFPWT
AFZJQ
AGQXC
AGUTN
AIACR
AIWBW
AJBDE
AJEEA
ALAGY
ALMA_UNASSIGNED_HOLDINGS
AMBMR
AMYDB
ATGXG
ATUGU
AZBYB
AZVAB
BAFTC
BCRHZ
BDRZF
BHBCM
BMXJE
BROTX
BRXPI
BY8
C45
CS3
D-6
D-7
D-E
D-F
DCZOG
DPXWK
DR2
DRFUL
DRMAN
DRSTM
DU5
EBS
ESX
EX3
F00
F01
F04
F5P
FUBAC
G-S
G.N
GODZA
H.X
H13
HZI
HZ~
IHE
IX1
J0M
K48
KBYEO
KOP
L7B
LATKE
LC2
LC3
LEEKS
LITHE
LOXES
LP6
LP7
LUTES
LYRES
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N9A
NF~
NPM
O66
O9-
OAUYM
OCZFY
OIG
OJZSN
OPAEJ
OVD
OWPYF
P2P
P2W
P2X
P2Z
P4B
P4D
Q.N
Q11
QB0
R.K
ROL
ROX
RX1
SUPJJ
TEORI
UB1
V9Y
VVN
W8V
W99
WBKPD
WHWMO
WIH
WIJ
WIK
WOHZO
WOW
WQJ
WRC
WUP
WVDHM
WXI
XG1
YFH
ZZTAW
~IA
~WT
AAYXX
CITATION
7X8
ID FETCH-LOGICAL-c214t-bd0373d41b63e03b0ee6eb4e448098bb03792e15626886ebbdd604b3f1b06473
ISSN 0007-0963
1365-2133
IngestDate Sat Oct 26 04:05:56 EDT 2024
Fri Nov 22 03:29:48 EST 2024
Sat Nov 02 12:28:55 EDT 2024
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 4
Language English
License The Author(s) 2024. Published by Oxford University Press on behalf of British Association of Dermatologists.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c214t-bd0373d41b63e03b0ee6eb4e448098bb03792e15626886ebbdd604b3f1b06473
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0009-0008-9887-8159
OpenAccessLink https://academic.oup.com/bjd/advance-article-pdf/doi/10.1093/bjd/ljae207/58084587/ljae207.pdf
PMID 38832950
PQID 3064582399
PQPubID 23479
ParticipantIDs proquest_miscellaneous_3064582399
crossref_primary_10_1093_bjd_ljae207
pubmed_primary_38832950
PublicationCentury 2000
PublicationDate 2024-Jun-04
PublicationDateYYYYMMDD 2024-06-04
PublicationDate_xml – month: 06
  year: 2024
  text: 2024-Jun-04
  day: 04
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
PublicationTitle British journal of dermatology (1951)
PublicationTitleAlternate Br J Dermatol
PublicationYear 2024
References Woo (2024071213254204900_ljae207-B7) 2021; 11
Bahloul (2024071213254204900_ljae207-B26)
Satoh (2024071213254204900_ljae207-B12) 2020; 48
Deng (2024071213254204900_ljae207-B4) 2022; 9
Huang (2024071213254204900_ljae207-B22) 2020; 140
Kowalski (2024071213254204900_ljae207-B17) 2019; 12
Polking (2024071213254204900_ljae207-B14) 2018; 32
U.S. Food & Drug Administration (2024071213254204900_ljae207-B18)
Højen (2024071213254204900_ljae207-B25) 2012; 51
Schneider (2024071213254204900_ljae207-B27) 1984; 59
Zeidler (2024071213254204900_ljae207-B11) 2018; 36
Morgan (2024071213254204900_ljae207-B20) 2022; 187
Kolli (2024071213254204900_ljae207-B29) 2019; 12
Boozalis (2024071213254204900_ljae207-B6) 2018; 79
Wolf (2024071213254204900_ljae207-B24) 2019; 48
Pereira (2024071213254204900_ljae207-B1) 2018; 32
Zeidler (2024071213254204900_ljae207-B3) 2016; 20
Stander (2024071213254204900_ljae207-B23) 2021; 2
Satoh (2024071213254204900_ljae207-B30) 2020; 48
Fostini (2024071213254204900_ljae207-B9) 2013; 24
Kwatra (2024071213254204900_ljae207-B16)
Saco (2024071213254204900_ljae207-B28) 2015; 65
Stander (2024071213254204900_ljae207-B19) 2020; 100
Stander (2024071213254204900_ljae207-B15) 2020; 382
Parthasarathy (2024071213254204900_ljae207-B5) 2022; 9
Ryczek (2024071213254204900_ljae207-B21) 2020; 100
Ständer (2024071213254204900_ljae207-B13) 2020; 5
Pereira (2024071213254204900_ljae207-B10) 2018; 32
Elmariah (2024071213254204900_ljae207-B2) 2021; 84
Whang (2024071213254204900_ljae207-B8) 2022; 86
References_xml – volume: 51
  start-page: 529
  year: 2012
  ident: 2024071213254204900_ljae207-B25
  article-title: Snomed CT implementation
  publication-title: Methods Inf Med
  doi: 10.3414/ME11-02-0023
  contributor:
    fullname: Højen
– volume: 36
  start-page: 189
  year: 2018
  ident: 2024071213254204900_ljae207-B11
  article-title: Prurigo nodularis and its management
  publication-title: Dermatol Clin
  doi: 10.1016/j.det.2018.02.003
  contributor:
    fullname: Zeidler
– ident: 2024071213254204900_ljae207-B16
  contributor:
    fullname: Kwatra
– volume: 100
  year: 2020
  ident: 2024071213254204900_ljae207-B19
  article-title: Epidemiology of prurigo nodularis compared with psoriasis in Germany: a claims database analysis
  publication-title: Acta Derm Venereol
  doi: 10.2340/00015555-3655
  contributor:
    fullname: Stander
– volume: 65
  start-page: 221
  year: 2015
  ident: 2024071213254204900_ljae207-B28
  article-title: Prurigo nodularis: picking the right treatment
  publication-title: J Fam Pract
  contributor:
    fullname: Saco
– volume: 20
  start-page: 37
  year: 2016
  ident: 2024071213254204900_ljae207-B3
  article-title: The pathogenesis of prurigo nodularis – ‘Super-Itch’ in exploration
  publication-title: Eur J Pain
  doi: 10.1002/ejp.767
  contributor:
    fullname: Zeidler
– volume: 11
  start-page: 95
  year: 2021
  ident: 2024071213254204900_ljae207-B7
  article-title: Epidemiology, comorbidities, and prescription patterns of Korean prurigo nodularis patients: a multi-institution study
  publication-title: J Clin Med
  doi: 10.3390/jcm11010095
  contributor:
    fullname: Woo
– volume: 2
  start-page: 28
  year: 2021
  ident: 2024071213254204900_ljae207-B23
  article-title: Prevalence of prurigo nodularis in the United States of America: a retrospective database analysis
  publication-title: JAAD Int
  doi: 10.1016/j.jdin.2020.10.009
  contributor:
    fullname: Stander
– volume: 84
  start-page: 747
  year: 2021
  ident: 2024071213254204900_ljae207-B2
  article-title: Practical approaches for diagnosis and management of prurigo nodularis: United States expert panel consensus
  publication-title: J Am Acad Dermatol
  doi: 10.1016/j.jaad.2020.07.025
  contributor:
    fullname: Elmariah
– volume: 48
  start-page: e414-31
  year: 2020
  ident: 2024071213254204900_ljae207-B12
  article-title: guidelines for the ­diagnosis and treatment of prurigo
  publication-title: J Dermatol
  contributor:
    fullname: Satoh
– volume: 100
  year: 2020
  ident: 2024071213254204900_ljae207-B21
  article-title: Prevalence of prurigo nodularis in Poland
  publication-title: Acta Derm Venereol
  doi: 10.2340/00015555-3518
  contributor:
    fullname: Ryczek
– volume: 32
  start-page: 1059
  year: 2018
  ident: 2024071213254204900_ljae207-B1
  article-title: European academy of dermatology and venereology European prurigo project: expert consensus on the definition, classification and terminology of chronic prurigo
  publication-title: J Eur Acad Dermatol Venereol
  doi: 10.1111/jdv.14570
  contributor:
    fullname: Pereira
– volume: 32
  start-page: 2224
  year: 2018
  ident: 2024071213254204900_ljae207-B10
  article-title: Prurigo nodularis: a physician survey to evaluate current perceptions of its classification, clinical experience and unmet need
  publication-title: J Eur Acad Dermatol Venereol
  doi: 10.1111/jdv.15107
  contributor:
    fullname: Pereira
– volume: 32
  start-page: 1754
  year: 2018
  ident: 2024071213254204900_ljae207-B14
  article-title: Prurigo Activity Score (PAS): validity and reliability of a new instrument to monitor chronic prurigo
  publication-title: J Eur Acad Dermatol Venereol
  doi: 10.1111/jdv.15040
  contributor:
    fullname: Polking
– volume: 382
  start-page: 706
  year: 2020
  ident: 2024071213254204900_ljae207-B15
  article-title: Trial of nemolizumab in ­moderate-to-severe prurigo nodularis
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1908316
  contributor:
    fullname: Stander
– volume: 86
  start-page: 573
  year: 2022
  ident: 2024071213254204900_ljae207-B8
  article-title: Health-related quality of life and economic burden of prurigo nodularis
  publication-title: J Am Acad Dermatol
  doi: 10.1016/j.jaad.2021.05.036
  contributor:
    fullname: Whang
– volume: 48
  year: 2019
  ident: 2024071213254204900_ljae207-B24
  article-title: Data resource profile: Clinical Practice Research Datalink (CPRD) Aurum
  publication-title: Int J Epidemiol
  doi: 10.1093/ije/dyz034
  contributor:
    fullname: Wolf
– volume: 5
  start-page: e42
  year: 2020
  ident: 2024071213254204900_ljae207-B13
  article-title: IFSI-guideline on chronic prurigo including prurigo nodularis
  publication-title: Itch
  doi: 10.1097/itx.0000000000000042
  contributor:
    fullname: Ständer
– ident: 2024071213254204900_ljae207-B18
  contributor:
    fullname: U.S. Food & Drug Administration
– volume: 187
  start-page: 188
  year: 2022
  ident: 2024071213254204900_ljae207-B20
  article-title: Epidemiology of prurigo nodularis in England: a retrospective database analysis
  publication-title: Br J Dermatol
  doi: 10.1111/bjd.21032
  contributor:
    fullname: Morgan
– volume: 12
  start-page: 345
  year: 2019
  ident: 2024071213254204900_ljae207-B29
  article-title: Treatment-resistant prurigo nodularis
  publication-title: Clin Cosmet Investig Dermatol
  doi: 10.2147/CCID.S208964
  contributor:
    fullname: Kolli
– volume: 79
  start-page: 714
  year: 2018
  ident: 2024071213254204900_ljae207-B6
  article-title: Ethnic differences and comorbidities of 909 prurigo nodularis patients
  publication-title: J Am Acad Dermatol
  doi: 10.1016/j.jaad.2018.04.047
  contributor:
    fullname: Boozalis
– volume: 9
  start-page: 1022889
  year: 2022
  ident: 2024071213254204900_ljae207-B4
  article-title: Extracellular matrix and dermal nerve growth factor dysregulation in prurigo nodularis compared to atopic dermatitis
  publication-title: Front Med (Lausanne)
  doi: 10.3389/fmed.2022.1022889
  contributor:
    fullname: Deng
– volume: 140
  start-page: 480
  year: 2020
  ident: 2024071213254204900_ljae207-B22
  article-title: Real-world prevalence of prurigo nodularis and burden of associated diseases
  publication-title: J Invest Dermatol
  doi: 10.1016/j.jid.2019.07.697
  contributor:
    fullname: Huang
– volume: 12
  start-page: 163
  year: 2019
  ident: 2024071213254204900_ljae207-B17
  article-title: Treatment-resistant prurigo nodularis: challenges and solutions
  publication-title: Clin Cosmet Investig Dermatol
  doi: 10.2147/CCID.S188070
  contributor:
    fullname: Kowalski
– volume: 48
  start-page: e414-31
  year: 2020
  ident: 2024071213254204900_ljae207-B30
  article-title: guidelines for the diagnosis and treatment of prurigo
  publication-title: J Dermatol
  contributor:
    fullname: Satoh
– volume: 9
  start-page: 1011142
  year: 2022
  ident: 2024071213254204900_ljae207-B5
  article-title: Circulating plasma IL-13 and periostin are dysregulated type 2 inflammatory biomarkers in prurigo nodularis: a cluster analysis
  publication-title: Front Med (Lausanne)
  doi: 10.3389/fmed.2022.1011142
  contributor:
    fullname: Parthasarathy
– volume: 59
  year: 1984
  ident: 2024071213254204900_ljae207-B27
  article-title: [Efficacy and safety of topical 0.05% diflorasone diacetate (florone) cream/ointment in patients with acute/chronic dermatitis]
  publication-title: Z Hautkr
  contributor:
    fullname: Schneider
– volume: 24
  start-page: 458
  year: 2013
  ident: 2024071213254204900_ljae207-B9
  article-title: Prurigo nodularis: an update on etiopathogenesis and therapy
  publication-title: J Dermatolog Treat
  doi: 10.3109/09546634.2013.814759
  contributor:
    fullname: Fostini
– ident: 2024071213254204900_ljae207-B26
  contributor:
    fullname: Bahloul
SSID ssj0013050
Score 2.4922347
Snippet Prurigo nodularis (PN) is a pruritic skin disease characterised by multiple, intensely itchy skin nodules in symmetrically distributed areas of the...
Prurigo nodularis (PN) is a pruritic skin disease characterized by multiple intensely itchy skin nodules in symmetrically distributed areas of the extremities....
SourceID proquest
crossref
pubmed
SourceType Aggregation Database
Index Database
StartPage 548
Title Prevalence, Incidence and Treatment Patterns of Prurigo Nodularis in England: A Retrospective Database Analysis
URI https://www.ncbi.nlm.nih.gov/pubmed/38832950
https://www.proquest.com/docview/3064582399
Volume 191
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1La9wwEBabFEovpe9uX6iQnlI3kiU72t76cOghj0JdyM1IK7lNWOxlsz7033dGku1d0kJ66MUsEhqWmY-RRvpmhpA9w-e5UYYl1liBLcxMorjWidHYDEn5ElR4dfHt8PRcfS5kMZn0TcbGsf9qaRgDW2Pm7D9YexAKA_AbbA5fsDp8b2R3rMmkfSYRag9v0n3X0MCUHFjlS19WM1DglqsOQvR2v2ktclIvPEM2NvcIudArt161fU7mPpJKcfMDkaGgydbDcCyStFGRwqLzX4daT2_8ixrfuH_4qH8u2m4RDvPNhR5xZq_n_ocF2IoYJ86w1_evYcUJEilDflqx-BFRHy80UumJV3LDB3viHQ_1Md65P4z1jjv0-YoIlRtuOAvVO69tD6F0lrlE0y8utUtDx93tMtynZ9XR9-PjqizOyx1yKwUPhg5UiK_j8xTL2JDQB_8qJn6C-AMQfhBFbx91_hK_-HNMeY_cjQEI_RCQc59MXPOA3D6JFIuHpB0B9JYO8KGABTrAh_bwoW1NI3zoAB9YRSN83lNNt8BDe_DQHjyPSHlUlJ--JLErRzJPuVwnxjJxKKzkJheOCcOcy52RDuJ8NlPGwOwsdRzO1blSMGOszZk0ouYGE5vFY7LbtI17SqhM5zOZ1ZqnDgKLrDayniPXwGopZeayKdnr9VctQ-2VKnAmRAVqrqKap-R1r9sKfCM-eOnGtd1VhdF1pjB7e0qeBKUPgoSCvWyWsWc3WP2c3BmB-oLsrlede0l2rmz3yuPiNxhRj7I
link.rule.ids 315,782,786,27933,27934
linkProvider Wiley-Blackwell
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Prevalence%2C+incidence+and+treatment+patterns+of+prurigo+nodularis+in+England%3A+a+retrospective+database+analysis&rft.jtitle=British+journal+of+dermatology+%281951%29&rft.au=Bahloul%2C+Donia&rft.au=Hudson%2C+Richard&rft.au=Balogh%2C+Orsolya&rft.au=Mathias%2C+Elgan&rft.date=2024-06-04&rft.issn=1365-2133&rft.eissn=1365-2133&rft.volume=191&rft.issue=4&rft.spage=548&rft_id=info:doi/10.1093%2Fbjd%2Fljae207&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0007-0963&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0007-0963&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0007-0963&client=summon